Lexaria Bioscience Corp.

LEXX Healthcare Biotechnology

Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024. In the quarter to May 2026, revenue fell 89.1%, EPS grew 61.9% and free cash flow grew 53.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

2.92 0.07 −2.34%
Market cap
$6.3M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
4/9
Altman Z
−23.89
Beneish M
−3.56
Dividend safety
n/a
May '26 Feb '26 Nov '25 Aug '25 Older periods
Piotroski F-Score
— 5 — 4

+8 more TTM periods

ROE
(162.60%) (146.94%) (155.10%) (231.96%)
ROA
(134.20%) (125.68%) (136.24%) (182.50%)
ROIC
(662.56%) (628.69%) (6,795.20%) (1,168.81%)
Return on Tangible Assets
(197.72%) (164.35%) (261.80%) (540.28%)
Average Days of Receivables
0.00 28.28 0.00 190.49
Free Cash Flow per Share
(4.55) (5.81) (6.15) (8.79)
Free Cash Flow
(7.53) (9.47) (8.78) (10.55)
Other line items

Show all line items

Columns are period end dates